Skip to main content
Top
Gepubliceerd in: Child Psychiatry & Human Development 5/2021

07-10-2020 | Original Article

Folinic Acid as Adjunctive Therapy in Treatment of Inappropriate Speech in Children with Autism: A Double-Blind and Placebo-Controlled Randomized Trial

Auteurs: Neda Batebi, Hossein Sanjari Moghaddam, Alireza Hasanzadeh, Yousef Fakour, Mohammad Reza Mohammadi, Shahin Akhondzadeh

Gepubliceerd in: Child Psychiatry & Human Development | Uitgave 5/2021

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

This is a double-blind, placebo-controlled randomized trial to investigate the potential therapeutic effects of folinic acid/placebo as an adjuvant to risperidone on inappropriate speech and other behavioral symptoms of autism spectrum disorder (ASD). Fifty-five ASD children (age (mean ± standard deviation) = 13.40 ± 2.00; male/female: 35/20) were evaluated for behavioral symptoms at baseline, week 5, and week 10 using the aberrant behavior checklist-community (ABC-C). Folinic acid dosage was 2 mg/kg up to 50 mg per day for the entire course of the study. The repeated measures analysis showed significant effect for time × treatment interaction on inappropriate speech (F = 3.51; df = 1.61; P = 0.044), stereotypic behavior (F = 4.02; df = 1.37; P = 0.036), and hyperactivity/noncompliance (F = 6.79; df = 1.66; P = 0.003) subscale scores. In contrast, no significant effect for time × treatment interaction was found on lethargy/social withdrawal (F = 1.06; df = 1.57; P = 0.336) and irritability (F = 2.86; df = 1.91; P = 0.064) subscale scores. Our study provided preliminary evidence suggesting that folinic acid could be recommended as a beneficial complementary supplement for alleviating speech and behavioral symptoms in children with ASD.
Clinical trial registeration: This trial was registered in the Iranian Registry of Clinical Trials (www.​irct.​ir; No. IRCT20090117001556N114).
Literatuur
1.
2.
go back to reference Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG (2015) The epidemiology and global burden of autism spectrum disorders. Psychol Med 45:601–613PubMedCrossRef Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG (2015) The epidemiology and global burden of autism spectrum disorders. Psychol Med 45:601–613PubMedCrossRef
3.
go back to reference American Psychiatric Association (2013) Diagnostic and statistical manual of mental sisorders (DSM–5), p 947 American Psychiatric Association (2013) Diagnostic and statistical manual of mental sisorders (DSM–5), p 947
4.
go back to reference Charman T, Jones CR, Pickles A, Simonoff E, Baird G, Happe F (2011) Defining the cognitive phenotype of autism. Brain Res 1380:10–21PubMedCrossRef Charman T, Jones CR, Pickles A, Simonoff E, Baird G, Happe F (2011) Defining the cognitive phenotype of autism. Brain Res 1380:10–21PubMedCrossRef
5.
go back to reference Charman T, Pickles A, Simonoff E, Chandler S, Loucas T, Baird G (2011) IQ in children with autism spectrum disorders: data from the Special Needs and Autism Project (SNAP). Psychol Med 41:619–627PubMedCrossRef Charman T, Pickles A, Simonoff E, Chandler S, Loucas T, Baird G (2011) IQ in children with autism spectrum disorders: data from the Special Needs and Autism Project (SNAP). Psychol Med 41:619–627PubMedCrossRef
6.
go back to reference Helverschou SB, Bakken TL, Martinsen H (2011) Psychiatric disorders in people with autism spectrum disorders: phenomenology and recognition. In: Matson JL, Sturmey P (eds) International handbook of autism and pervasive developmental disorders. Springer, New York, pp 53–74CrossRef Helverschou SB, Bakken TL, Martinsen H (2011) Psychiatric disorders in people with autism spectrum disorders: phenomenology and recognition. In: Matson JL, Sturmey P (eds) International handbook of autism and pervasive developmental disorders. Springer, New York, pp 53–74CrossRef
7.
go back to reference Perry A, Flanagan HE, Dunn Geier J, Freeman NL (2009) Brief report: the Vineland adaptive behavior scales in young children with autism spectrum disorders at different cognitive levels. J Autism Dev Disord 39:1066–1078PubMedCrossRef Perry A, Flanagan HE, Dunn Geier J, Freeman NL (2009) Brief report: the Vineland adaptive behavior scales in young children with autism spectrum disorders at different cognitive levels. J Autism Dev Disord 39:1066–1078PubMedCrossRef
8.
go back to reference Shriberg LD, Paul R, Black LM, van Santen JP (2011) The hypothesis of apraxia of speech in children with autism spectrum disorder. J Autism Dev Disord 41:405–426PubMedPubMedCentralCrossRef Shriberg LD, Paul R, Black LM, van Santen JP (2011) The hypothesis of apraxia of speech in children with autism spectrum disorder. J Autism Dev Disord 41:405–426PubMedPubMedCentralCrossRef
9.
go back to reference Vogindroukas I, Papageorgiou V, Vostanis P (2003) Pattern of semantic errors in autism: a brief research report. Autism 7:195–203PubMedCrossRef Vogindroukas I, Papageorgiou V, Vostanis P (2003) Pattern of semantic errors in autism: a brief research report. Autism 7:195–203PubMedCrossRef
10.
go back to reference Rapin I, Dunn M (2003) Update on the language disorders of individuals on the autistic spectrum. Brain Dev 25:166–172PubMedCrossRef Rapin I, Dunn M (2003) Update on the language disorders of individuals on the autistic spectrum. Brain Dev 25:166–172PubMedCrossRef
11.
go back to reference Jordan R (1993) The nature of the linguistic and communication difficulties of children with autism. In: Messer DJ, Turner GJ (eds) Critical influences on child language acquisition and development. Palgrave Macmillan, London, pp 229–249CrossRef Jordan R (1993) The nature of the linguistic and communication difficulties of children with autism. In: Messer DJ, Turner GJ (eds) Critical influences on child language acquisition and development. Palgrave Macmillan, London, pp 229–249CrossRef
12.
go back to reference Mody M, Belliveau JW (2013) Speech and language impairments in autism: insights from behavior and neuroimaging. N Am J Med Sci (Boston) 5:157–161CrossRef Mody M, Belliveau JW (2013) Speech and language impairments in autism: insights from behavior and neuroimaging. N Am J Med Sci (Boston) 5:157–161CrossRef
13.
go back to reference Kasari C, Brady N, Lord C, Tager-Flusberg H (2013) Assessing the minimally verbal school-aged child with autism spectrum disorder. Autism Res 6:479–493PubMedPubMedCentralCrossRef Kasari C, Brady N, Lord C, Tager-Flusberg H (2013) Assessing the minimally verbal school-aged child with autism spectrum disorder. Autism Res 6:479–493PubMedPubMedCentralCrossRef
14.
go back to reference Tager-Flusberg H, Kasari C (2013) Minimally verbal school-aged children with autism spectrum disorder: the neglected end of the spectrum. Autism Res 6:468–478PubMedCrossRef Tager-Flusberg H, Kasari C (2013) Minimally verbal school-aged children with autism spectrum disorder: the neglected end of the spectrum. Autism Res 6:468–478PubMedCrossRef
15.
go back to reference Akhondzadeh S, Fallah J, Mohammadi MR, Imani R, Mohammadi M, Salehi B et al (2010) Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry 34:32–36PubMedCrossRef Akhondzadeh S, Fallah J, Mohammadi MR, Imani R, Mohammadi M, Salehi B et al (2010) Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry 34:32–36PubMedCrossRef
16.
go back to reference Behmanesh H, Moghaddam HS, Mohammadi MR, Akhondzadeh S (2019) Risperidone combination therapy with propentofylline for treatment of irritability in autism spectrum disorders: a randomized, double-blind, placebo-controlled clinical trial. Clin Neuropharmacol 42:189–196PubMedCrossRef Behmanesh H, Moghaddam HS, Mohammadi MR, Akhondzadeh S (2019) Risperidone combination therapy with propentofylline for treatment of irritability in autism spectrum disorders: a randomized, double-blind, placebo-controlled clinical trial. Clin Neuropharmacol 42:189–196PubMedCrossRef
17.
go back to reference Hendouei F, Sanjari Moghaddam H, Mohammadi MR, Taslimi N, Rezaei F, Akhondzadeh S (Resveratrol as adjunctive therapy in treatment of irritability in children with autism: a double-blind and placebo-controlled randomized trial. n/a Hendouei F, Sanjari Moghaddam H, Mohammadi MR, Taslimi N, Rezaei F, Akhondzadeh S (Resveratrol as adjunctive therapy in treatment of irritability in children with autism: a double-blind and placebo-controlled randomized trial. n/a
18.
go back to reference Robb AS (2010) Managing irritability and aggression in autism spectrum disorders in children and adolescents. Dev Disabil Res Rev 16:258–264PubMedCrossRef Robb AS (2010) Managing irritability and aggression in autism spectrum disorders in children and adolescents. Dev Disabil Res Rev 16:258–264PubMedCrossRef
19.
go back to reference Jahangard L, Akbarian S, Haghighi M, Ahmadpanah M, Keshavarzi A, Bajoghli H et al (2017) Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed—results from a randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res 251:182–191PubMedCrossRef Jahangard L, Akbarian S, Haghighi M, Ahmadpanah M, Keshavarzi A, Bajoghli H et al (2017) Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed—results from a randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res 251:182–191PubMedCrossRef
20.
go back to reference Johnson MH (2011) Interactive Specialization: a domain-general framework for human functional brain development? Dev Cogn Neurosci 1:7–21PubMedCrossRef Johnson MH (2011) Interactive Specialization: a domain-general framework for human functional brain development? Dev Cogn Neurosci 1:7–21PubMedCrossRef
21.
go back to reference Jones EJH, Gliga T, Bedford R, Charman T, Johnson MH (2014) Developmental pathways to autism: a review of prospective studies of infants at risk. Neurosci Biobehav Rev 39:1–33PubMedPubMedCentralCrossRef Jones EJH, Gliga T, Bedford R, Charman T, Johnson MH (2014) Developmental pathways to autism: a review of prospective studies of infants at risk. Neurosci Biobehav Rev 39:1–33PubMedPubMedCentralCrossRef
22.
go back to reference Vahabzadeh A, McDougle CJ (2013) Maternal folic acid supplementation and risk of autism. Jama 309:2208PubMedCrossRef Vahabzadeh A, McDougle CJ (2013) Maternal folic acid supplementation and risk of autism. Jama 309:2208PubMedCrossRef
23.
go back to reference Ramaekers VT, Rothenberg SP, Sequeira JM, Opladen T, Blau N, Quadros EV et al (2005) Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. N Engl J Med 352:1985–1991PubMedCrossRef Ramaekers VT, Rothenberg SP, Sequeira JM, Opladen T, Blau N, Quadros EV et al (2005) Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. N Engl J Med 352:1985–1991PubMedCrossRef
24.
go back to reference Ramaekers VT, Blau N, Sequeira JM, Nassogne MC, Quadros EV (2007) Folate receptor autoimmunity and cerebral folate deficiency in low-functioning autism with neurological deficits. Neuropediatrics 38:276–281PubMedCrossRef Ramaekers VT, Blau N, Sequeira JM, Nassogne MC, Quadros EV (2007) Folate receptor autoimmunity and cerebral folate deficiency in low-functioning autism with neurological deficits. Neuropediatrics 38:276–281PubMedCrossRef
25.
go back to reference Ramaekers VT, Hausler M, Opladen T, Heimann G, Blau N (2002) Psychomotor retardation, spastic paraplegia, cerebellar ataxia and dyskinesia associated with low 5-methyltetrahydrofolate in cerebrospinal fluid: a novel neurometabolic condition responding to folinic acid substitution. Neuropediatrics 33:301–308PubMedCrossRef Ramaekers VT, Hausler M, Opladen T, Heimann G, Blau N (2002) Psychomotor retardation, spastic paraplegia, cerebellar ataxia and dyskinesia associated with low 5-methyltetrahydrofolate in cerebrospinal fluid: a novel neurometabolic condition responding to folinic acid substitution. Neuropediatrics 33:301–308PubMedCrossRef
26.
go back to reference Steenweg-de Graaff J, Ghassabian A, Jaddoe VW, Tiemeier H, Roza SJ (2015) Folate concentrations during pregnancy and autistic traits in the offspring. The Generation R Study. Eur J Public Health 25:431–433PubMedCrossRef Steenweg-de Graaff J, Ghassabian A, Jaddoe VW, Tiemeier H, Roza SJ (2015) Folate concentrations during pregnancy and autistic traits in the offspring. The Generation R Study. Eur J Public Health 25:431–433PubMedCrossRef
27.
go back to reference Suren P, Roth C, Bresnahan M, Haugen M, Hornig M, Hirtz D et al (2013) Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. Jama 309:570–577PubMedPubMedCentralCrossRef Suren P, Roth C, Bresnahan M, Haugen M, Hornig M, Hirtz D et al (2013) Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. Jama 309:570–577PubMedPubMedCentralCrossRef
28.
go back to reference Frye RE, Sequeira JM, Quadros EV, James SJ, Rossignol DA (2013) Cerebral folate receptor autoantibodies in autism spectrum disorder. Molecular psychiatry 18:369–381PubMedCrossRef Frye RE, Sequeira JM, Quadros EV, James SJ, Rossignol DA (2013) Cerebral folate receptor autoantibodies in autism spectrum disorder. Molecular psychiatry 18:369–381PubMedCrossRef
29.
go back to reference James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW et al (2004) Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 80:1611–1617PubMedCrossRef James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW et al (2004) Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 80:1611–1617PubMedCrossRef
30.
go back to reference James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH et al (2006) Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 141b:947–956PubMedPubMedCentralCrossRef James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH et al (2006) Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 141b:947–956PubMedPubMedCentralCrossRef
31.
go back to reference Biswas S, Chida AS, Rahman I (2006) Redox modifications of protein-thiols: emerging roles in cell signaling. Biochem Pharmacol 71:551–564PubMedCrossRef Biswas S, Chida AS, Rahman I (2006) Redox modifications of protein-thiols: emerging roles in cell signaling. Biochem Pharmacol 71:551–564PubMedCrossRef
32.
33.
go back to reference Pastore A, Federici G, Bertini E, Piemonte F (2003) Analysis of glutathione: implication in redox and detoxification. Clin Chim Acta 333:19–39PubMedCrossRef Pastore A, Federici G, Bertini E, Piemonte F (2003) Analysis of glutathione: implication in redox and detoxification. Clin Chim Acta 333:19–39PubMedCrossRef
34.
go back to reference Schafer FQ, Buettner GR (2001) Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30:1191–1212PubMedCrossRef Schafer FQ, Buettner GR (2001) Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30:1191–1212PubMedCrossRef
35.
go back to reference Sequeira JM, Desai A, Berrocal-Zaragoza MI, Murphy MM, Fernandez-Ballart JD, Quadros EV (2016) Exposure to folate receptor alpha antibodies during gestation and weaning leads to severe behavioral deficits in rats: a pilot study. PLoS One 11:e0152249PubMedPubMedCentralCrossRef Sequeira JM, Desai A, Berrocal-Zaragoza MI, Murphy MM, Fernandez-Ballart JD, Quadros EV (2016) Exposure to folate receptor alpha antibodies during gestation and weaning leads to severe behavioral deficits in rats: a pilot study. PLoS One 11:e0152249PubMedPubMedCentralCrossRef
36.
go back to reference Anonymous (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama 310:2191–2194CrossRef Anonymous (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama 310:2191–2194CrossRef
37.
go back to reference Association AP (2013) Diagnostic and statistical manual of mental disorders 5th edition: DSM 5. American Psychiatric Association, ArlingtonCrossRef Association AP (2013) Diagnostic and statistical manual of mental disorders 5th edition: DSM 5. American Psychiatric Association, ArlingtonCrossRef
38.
go back to reference Lord C, Rutter M, Le Couteur A (1994) Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24:659–685PubMedCrossRef Lord C, Rutter M, Le Couteur A (1994) Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24:659–685PubMedCrossRef
39.
go back to reference Frye RE, Slattery J, Delhey L, Furgerson B, Strickland T, Tippett M et al (2018) Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Mol Psychiatry 23:247–256PubMedCrossRef Frye RE, Slattery J, Delhey L, Furgerson B, Strickland T, Tippett M et al (2018) Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Mol Psychiatry 23:247–256PubMedCrossRef
40.
go back to reference Ghaleiha A, Mohammadi E, Mohammadi MR, Farokhnia M, Modabbernia A, Yekehtaz H et al (2013) Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Paediatr Drugs 15:505–514PubMedCrossRef Ghaleiha A, Mohammadi E, Mohammadi MR, Farokhnia M, Modabbernia A, Yekehtaz H et al (2013) Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Paediatr Drugs 15:505–514PubMedCrossRef
41.
go back to reference Ghaleiha A, Rasa SM, Nikoo M, Farokhnia M, Mohammadi MR, Akhondzadeh S (2015) A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: effects on aberrant behavior in children with autism. Psychiatry Res 229:181–187PubMedCrossRef Ghaleiha A, Rasa SM, Nikoo M, Farokhnia M, Mohammadi MR, Akhondzadeh S (2015) A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: effects on aberrant behavior in children with autism. Psychiatry Res 229:181–187PubMedCrossRef
42.
go back to reference Khalaj M, Saghazadeh A, Shirazi E, Shalbafan MR, Alavi K, Shooshtari MH et al (2018) Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial. J Psychiatr Res 103:104–111PubMedCrossRef Khalaj M, Saghazadeh A, Shirazi E, Shalbafan MR, Alavi K, Shooshtari MH et al (2018) Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial. J Psychiatr Res 103:104–111PubMedCrossRef
43.
go back to reference Chouinard G, Margolese HC (2005) Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res 76:247–265PubMedCrossRef Chouinard G, Margolese HC (2005) Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res 76:247–265PubMedCrossRef
44.
go back to reference Jasbi M, Sadeghi Bahmani D, Karami G, Omidbeygi M, Peyravi M, Panahi A et al (2018) Influence of adjuvant mindfulness-based cognitive therapy (MBCT) on symptoms of post-traumatic stress disorder (PTSD) in veterans – results from a randomized control study. Cognitive Behaviour Therapy 47:431–446PubMedCrossRef Jasbi M, Sadeghi Bahmani D, Karami G, Omidbeygi M, Peyravi M, Panahi A et al (2018) Influence of adjuvant mindfulness-based cognitive therapy (MBCT) on symptoms of post-traumatic stress disorder (PTSD) in veterans – results from a randomized control study. Cognitive Behaviour Therapy 47:431–446PubMedCrossRef
45.
go back to reference Becker BJ (1988) Synthesizing standardized mean-change measures. Br J Math Stat Psychol 41:257–278CrossRef Becker BJ (1988) Synthesizing standardized mean-change measures. Br J Math Stat Psychol 41:257–278CrossRef
46.
go back to reference Frye RE, Melnyk S, Fuchs G, Reid T, Jernigan S, Pavliv O et al (2013) Effectiveness of methylcobalamin and folinic acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status. Autism Res Treat 2013:609705PubMedPubMedCentral Frye RE, Melnyk S, Fuchs G, Reid T, Jernigan S, Pavliv O et al (2013) Effectiveness of methylcobalamin and folinic acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status. Autism Res Treat 2013:609705PubMedPubMedCentral
47.
go back to reference Frye RE, James SJ (2014) Metabolic pathology of autism in relation to redox metabolism. Biomark Med 8:321–330PubMedCrossRef Frye RE, James SJ (2014) Metabolic pathology of autism in relation to redox metabolism. Biomark Med 8:321–330PubMedCrossRef
48.
go back to reference Schmidt RJ, Tancredi DJ, Ozonoff S, Hansen RL, Hartiala J, Allayee H et al (2012) Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (CHildhood Autism Risks from Genetics and Environment) case-control study. Am J Clin Nutr 96:80–89PubMedPubMedCentralCrossRef Schmidt RJ, Tancredi DJ, Ozonoff S, Hansen RL, Hartiala J, Allayee H et al (2012) Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (CHildhood Autism Risks from Genetics and Environment) case-control study. Am J Clin Nutr 96:80–89PubMedPubMedCentralCrossRef
50.
go back to reference Moretti P, Peters SU, Del Gaudio D, Sahoo T, Hyland K, Bottiglieri T et al (2008) Brief report: autistic symptoms, developmental regression, mental retardation, epilepsy, and dyskinesias in CNS folate deficiency. J Autism Dev Disord 38:1170–1177PubMedCrossRef Moretti P, Peters SU, Del Gaudio D, Sahoo T, Hyland K, Bottiglieri T et al (2008) Brief report: autistic symptoms, developmental regression, mental retardation, epilepsy, and dyskinesias in CNS folate deficiency. J Autism Dev Disord 38:1170–1177PubMedCrossRef
51.
go back to reference Desai A, Sequeira JM, Quadros EV (2016) The metabolic basis for developmental disorders due to defective folate transport. Biochimie 126:31–42PubMedCrossRef Desai A, Sequeira JM, Quadros EV (2016) The metabolic basis for developmental disorders due to defective folate transport. Biochimie 126:31–42PubMedCrossRef
52.
go back to reference Garcia-Cazorla A, Quadros EV, Nascimento A, Garcia-Silva MT, Briones P, Montoya J et al (2008) Mitochondrial diseases associated with cerebral folate deficiency. Neurology 70:1360–1362PubMedCrossRef Garcia-Cazorla A, Quadros EV, Nascimento A, Garcia-Silva MT, Briones P, Montoya J et al (2008) Mitochondrial diseases associated with cerebral folate deficiency. Neurology 70:1360–1362PubMedCrossRef
53.
go back to reference Ramaekers VT, Quadros EV, Sequeira JM (2013) Role of folate receptor autoantibodies in infantile autism. Mol Psychiatry 18:270–271PubMedCrossRef Ramaekers VT, Quadros EV, Sequeira JM (2013) Role of folate receptor autoantibodies in infantile autism. Mol Psychiatry 18:270–271PubMedCrossRef
54.
go back to reference Shoffner J, Trommer B, Thurm A, Farmer C, Langley WA, Soskey L et al (2016) CSF concentrations of 5-methyltetrahydrofolate in a cohort of young children with autism. Neurology 86:2258–2263PubMedPubMedCentralCrossRef Shoffner J, Trommer B, Thurm A, Farmer C, Langley WA, Soskey L et al (2016) CSF concentrations of 5-methyltetrahydrofolate in a cohort of young children with autism. Neurology 86:2258–2263PubMedPubMedCentralCrossRef
55.
go back to reference Sequeira JM, Ramaekers VT, Quadros EV (2013) The diagnostic utility of folate receptor autoantibodies in blood. Clin Chem Lab Med 51:545–554PubMedCrossRef Sequeira JM, Ramaekers VT, Quadros EV (2013) The diagnostic utility of folate receptor autoantibodies in blood. Clin Chem Lab Med 51:545–554PubMedCrossRef
56.
go back to reference Boarman DM, Baram J, Allegra CJ (1990) Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells. Biochem Pharmacol 40:2651–2660PubMedCrossRef Boarman DM, Baram J, Allegra CJ (1990) Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells. Biochem Pharmacol 40:2651–2660PubMedCrossRef
Metagegevens
Titel
Folinic Acid as Adjunctive Therapy in Treatment of Inappropriate Speech in Children with Autism: A Double-Blind and Placebo-Controlled Randomized Trial
Auteurs
Neda Batebi
Hossein Sanjari Moghaddam
Alireza Hasanzadeh
Yousef Fakour
Mohammad Reza Mohammadi
Shahin Akhondzadeh
Publicatiedatum
07-10-2020
Uitgeverij
Springer US
Gepubliceerd in
Child Psychiatry & Human Development / Uitgave 5/2021
Print ISSN: 0009-398X
Elektronisch ISSN: 1573-3327
DOI
https://doi.org/10.1007/s10578-020-01072-8

Andere artikelen Uitgave 5/2021

Child Psychiatry & Human Development 5/2021 Naar de uitgave